Severe Acute Respiratory Infections (SARI) surveillance in over-65-years-old patients: the experience of a University hospital (seasons 2017-2018 and 2018-2019)
Keywords:
Severe acute respiratory infections, surveillance, over-65-years-old patientsAbstract
Background. Influenza is a relevant public health problem, also due to the risk of complications. The most effective measure to prevent influenza is vaccination; therefore, at present, there is consensus among European countries, regarding the need for routine seasonal influenza vaccination of elderly and individuals at increased risk of severe influenza. At the same time, influenza surveillance is necessary to understand the viruses circulating and effectiveness of vaccination strategies. The present study reports the results of two seasons influenza surveillance (2017/2018 and 2018/2019) conduced in an University Hospital in Rome among hospitalized patients aged ≥65 years.
Study design. A prospective cohort study.
Methods. The study consisted of systematic daily screening of all admissions among patients aged ≥65 years meeting a syndromic SARI case definition during two consecutive influenza seasons: 2017/2018 and 2018/2019. Characteristics of patients and their risk factors were collected by a standardized questionnaire and nose-pharyngeal swabs were performed to each patient. Influenza vaccine effectiveness (IVE), rates of vaccinated subjects and case fatality rate were also evaluated.
Results. Influenza was laboratory confirmed in 11 (9.9%) of the 111 and 11 (9.6%) of the 115 enrolled patients in seasons 2017/18 and 2018/19, respectively. Adjusted IVE against all influenza type, calculated for each season, was 88.5% (95% CI: 38.9 to 97.8) and 61.7% (95% CI: -59.9 to 90.9) for 2017/2018 and 2018/2019 seasons, respectively. Our analysis shows a Case Fatality Rate of 2.7% and 4.3% for the 2017/18 and 2018/19 seasons, respectively.
Conclusions. The surveillance of SARI conduced in one hospital in Rome confirmed that influenza is an important cause of hospital admissions. Routine monitoring of infectious diseases and related aetiology associated with SARI, also at the local-level, is useful for targeting the right preventive measures.
References
1. World Health Organization (WHO). Fact sheet on influenza. 2020. Available on: https://www.who. int/en/news-room/fact-sheets/detail/influenza(seasonal). [Last accessed: 2021, Jan 11].
2. Rizzo C, Gesualdo F, Loconsole D, et al. Moderate Vaccine Effectiveness against Severe Acute Respiratory Infection Caused by A(H1N1)pdm09 Influenza Virus and No Effectiveness against
A(H3N2) Influenza Virus in the 2018/2019 Season in Italy. Vaccines (Basel) 2020; 30: 8(3): 427. doi: 10.3390/vaccines8030427.
3. Raviotta JM, Smith KJ, DePasse J, et al. Costeffectiveness and public health effect of influenza vaccine strategies for U.S. elderly adults. J Am Geriatr Soc 2016; 64(10): 2126-31. doi: 10.1111/jgs.14323. Epub 2016 Oct 6.
4. Bella A, Gesualdo F, Orsi A, et. al. Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 - 2018 season. Expert Rev Vaccines 2019; 18(6): 671-9. doi: 10.1080/14760584.2019.1627206. Epub 2019 Jun 13.
5. Napoli C, Fabiani M, Rizzo C, et al. Assessment of human influenza pandemic scenarios in Europe. Euro Surveill 2015; 20(7): 29-38. doi:
10.2807/1560-7917.es2015.20.7.21038.
6. Napoli C, Dente MG, Kärki T, et al. Screening for Infectious Diseases among Newly
Arrived Migrants: Experiences and Practices
in Non-EU Countries of the Mediterranean Basin and Black Sea. Int J Environ Res Public Health 2015; 12(12): 15550-8. doi: 10.3390/ ijerph121215002.
7. European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccination and antiviral use in Europe – Overview of vaccination recommendations and coverage rates in the EU Member States for the 2013–14 and 2014–15 influenza seasons. Stockholm: ECDC; 2016. Avalaible on: https://www.ecdc.europa.eu/ en/publications-data/seasonal-influenza-vaccination-europe-vaccination-recommendationsand-coverage-0. [Last accessed: 2021, Jan 11].
8. Demicheli V, Jefferson T, Di Pietrantonj C, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2018; 2: 004876.
9. Bulut O, Kilic G, Domínguez-Andrés J, Netea MG. Overcoming immune dysfunction in the elderly: trained immunity as a novel approach. Int Immunol 2020; 32(12): 741-53. doi: 10.1093/ intimm/dxaa052.
10. European Centre for Disease Prevention and Control (ECDC). Expert opinion on priority risk groups for influenza vaccination. Stockholm, August 2008. Available on: https://www.ecdc. europa.eu/en/publications-data/expert-opinionpriority-risk-groups-influenza-vaccination. [Last accessed: 2021, Jan 11].
11. Italian Ministry of Health. Prevention and Control for Influenza: recommendations for season 2018-2019. Italy. 2018. Available on: http://www. trovanorme.salute.gov.it/norme/renderNormsan Pdf?anno=2018&codLeg=64381&parte=1%20
&serie=null. [Last accessed: 2021, Jan 11].
12. Haq K, McElhaney JE. Immunosenescence: Influenza vaccination and the elderly. Curr Opin Immunol 2014; 29: 38-42. doi: 10.1016/j. coi.2014.03.008. Epub 2014 Apr 25.
13. World Health Organization (WHO). Overview of sentinel systems for hospitalized severe acute respiratory infections (SARI) represented in the weekly EuroFlu surveillance bulletin. Euro World Health Organization 2013. Available on: http://www.euro.who.int/__data/assets/ pdf_file/0005/186863/Overview-of-SARI-
Surveillance-Systems-final.pdf. [Last accessed: 2021, Jan 11].
14. Darvishian M, van den Heuvel ER, Bissielo A, et al. Effectiveness of seasonal influenza vaccination in community-dwelling elderly people: an individual participant data meta-analysis of test-negative design case-control studies. Lancet Respir Med 2017; 5(3): 200-211. doi: 10.1016/ S2213-2600(17)30043-7. Epub 2017 Feb 9.
15. Rizzo C, Viboud C, Montomoli E, et al. Influenzarelated mortality in the Italian elderly: no decline associated with increasing vaccination coverage.
Vaccine 2006; 24(42-43): 6468-75. doi: 10.1016/j. vaccine.2006.06.052. Epub 2006 Jul 7.
16. Capalbo C, Bertamino E, Zerbetto A, et al. No Evidence of SARS-CoV-2 Circulation in Rome (Italy) during the Pre-Pandemic Period: Results of a Retrospective Surveillance. Int J Environ Res Public Health 2020; 17(22): 8461. doi: 10.3390/ijerph17228461.
17. Istituto Superiore di Sanità (ISS). Sistema di Sorveglianza Integrata dell’Influenza (InfluNet). Available on: https://www.epicentro.iss.it/influenza/influnet. [Last accessed: 2021, Jan 11].
18. Maignan M, Viglino D, Hablot M, et al. Diagnostic accuracy of a rapid RT-PCR assay for point-of-care detection of influenza A/B virus at emergency department admission: A prospective evaluation during the 2017/2018 influenza season. PLoS One 2019; 14(5): e0216308. doi: 10.1371/journal.pone.0216308.
19. Iuliano AD, Roguski KM, Chang HH, et al; Global Seasonal Influenza-associated Mortality Collaborator Network. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 2018; 391(10127): 1285-1300. doi: 10.1016/S01406736(17)33293-2. Epub 2017 Dec 14.
20. Napoli, C, Riccardo F, Declich S, et al; National Working Group. An early warning system based on syndromic surveillance to detect potential health emergencies among migrants: results of a two-year experience in Italy. Int J Environ Res Public Health 2014; 11(8): 8529-41. doi: 10.3390/ijerph110808529.
21. Rondy M, Kissling E, Emborg HD, et al. Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. Euro Surveill 2018; 23(9): 18-00086. doi:
10.2807/1560-7917.ES.2018.23.9.18-00086.
22. European Centre for Disease Prevention and Control (ECDC). Annual Epidemiological
Report, Seasonal influenza, 2017-2018. Surveillance report. 2018. Available on: https://www. ecdc.europa.eu/en/publications-data/seasonalinfluenza-annual-epidemiological-report-2017 -18-season. [Last accessed: 2021, Jan 11].
23. Italian Ministry of Health. Influenza vaccination - Medium vaccination covers. Available on: http://www.salute.gov.it/portale/documentazione/p6_2_8_3_1.jsp?lingua=italiano&id=19. [Last accessed: 2021, Jan 11].
24. Butsashvili M, Kandelaki G, Zakhashvili
K, Machablishvili A, Avaliani N. InfluenzaAssociated Mortality in Georgia (2009-2011). Influenza Res Treat 2012; 12: 480763. https:// doi.org/10.1155/2012/480763.
25. Beresniak A, Rizzo C, Oxford J, et al. Costeffectiveness of public health interventions against human influenza pandemics in France: a methodological contribution from the FLURESP European Commission project. Eur J Public Health 2020; 30(1): 43-9. doi: 10.1093/eurpub/ckz074.
26, Qi L, Li Q, Ding XB, Gao Y, et al. Mortality burden from seasonal influenza in Chongqing, China, 2012-2018. Hum Vaccin Immunother 2020; 16(7): 1668-74. doi: 10.1080/21645515.2019.1693721. Epub 2020 Apr 28.
27. Chu EY, Englund JA, Huang D, et al. Impact of Rapid Influenza PCR Testing on Hospitalization and Antiviral Use: A Retrospective Cohort Study. J Med Virol 2015; 87(12): 2021-6. doi: 10.1002/jmv.24279. Epub 2015 Jun 12.
28. Kissling E, Rose A, Emborg HD, et al. Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019. Euro Surveill 2019; 24(8): 1900121. doi:
10.2807/1560-7917.ES.2019.24.1900121.
29. De Giglio O, Napoli C, Lovero G, et al. Antibiotic susceptibility of Legionella pneumophila strains isolated from hospital water systems in Southern Italy. Environ Res 2015; 142: 586-90. doi: 10.1016/j.envres.2015.08.013.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.